Ted Getz, MD
he/him/his
Clinical FellowDownloadHi-Res Photo
About
Copy Link
Titles
Clinical Fellow
Biography
Ted Getz is a hematology/oncology fellow at Yale University & Yale Comprehensive Cancer Center. He graduated from Case Western Reserve University School of Medicine in 2020 and completed a residency in internal medicine at Weill-Cornell/New York Presbyterian Hospital. His clinical and research interests focus on myeloid malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Dr. Getz is actively involved in outcomes research, clinical trial methodology, and the development of institutional and multi-institutional registries to advance the care of patients with hematologic cancers.
Last Updated on August 30, 2025.
Appointments
Medical Oncology and Hematology
Clinical FellowPrimary
Other Departments & Organizations
- Internal Medicine
- Medical Oncology and Hematology
Education & Training
- Resident
- New York Presbyterian/Weill Cornell Medical Center (2023)
- MD
- Case Western Reserve University School of Medicine (2020)
- BS
- The University of Chicago, Biological Chemistry (2015)
Board Certifications
Internal Medicine
- Certification Organization
- ABIM
- Original Certification Date
- 2023
Research
Copy Link
Overview
Medical Research Interests
Leukemia; Leukemia, Myeloid; Meta-Analysis; Multicenter Study
ORCID
0000-0001-9886-5624
Research at a Glance
Yale Co-Authors
Frequent collaborators of Ted Getz's published research.
Publications Timeline
A big-picture view of Ted Getz's research output by year.
Jan Philipp Bewersdorf, MD, FACP
Rory Shallis, MD
Amer Zeidan, MBBS
Maximilian Stahl, MD
Stuart Seropian, MD
10Publications
8Citations
Publications
2025
Avapritinib monotherapy induces rapid and deep remission of heavily treated, KIT D816H-mutated t(8;21) acute myeloid leukemia, a case report and literature review
Getz T, Bakirhan K, Seropian S, Shallis R. Avapritinib monotherapy induces rapid and deep remission of heavily treated, KIT D816H-mutated t(8;21) acute myeloid leukemia, a case report and literature review. Annals Of Hematology 2025, 104: 3889-3892. PMID: 40576687, PMCID: PMC12334448, DOI: 10.1007/s00277-025-06388-w.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsAcute myeloid leukemiaT(8;21) acute myeloid leukemiaDeep remissionKIT mutationsMyeloid leukemiaAllogeneic hematopoietic stem cell transplantationCore binding factor acute myeloid leukemiaHematopoietic stem cell transplantationTreatment of acute myeloid leukemiaFavorable risk diseaseStem cell transplantationTyrosine kinase inhibitorsT(8;21)Based chemotherapyOverall survivalSystemic mastocytosisCell transplantationRisk diseaseTargeted therapyCase reportKinase inhibitorsClinical challengeT(8;21Clinical investigationAvapritinibMore than just another IDH inhibitor: Insights from the HMPL-306 phase 1 trial
Getz T, Bewersdorf J. More than just another IDH inhibitor: Insights from the HMPL-306 phase 1 trial. Med 2025, 6: 100600. PMID: 40516517, DOI: 10.1016/j.medj.2025.100600.Peer-Reviewed Original ResearchMeSH Keywords and Concepts
2024
Targeted therapies for myelodysplastic syndromes/neoplasms (MDS): current landscape and future directions
Bidikian A, Bewersdorf J, Shallis R, Getz T, Stempel J, Kewan T, Stahl M, Zeidan A. Targeted therapies for myelodysplastic syndromes/neoplasms (MDS): current landscape and future directions. Expert Review Of Anticancer Therapy 2024, 24: 1131-1146. PMID: 39367718, DOI: 10.1080/14737140.2024.2414071.Peer-Reviewed Original ResearchCitationsAltmetricConceptsErythropoiesis-stimulating agentsTargeted therapyLR-MDSHR-MDSHypoxia-inducible factorAllogeneic hematopoietic stem cell transplantationLandscape of targeted therapiesHematopoietic stem cell transplantationHeterogeneous group of hematologic malignanciesGroup of hematologic malignanciesMolecular prognostic toolsDuration of responseStem cell transplantationTrial designClinical trial designHypomethylating agentsCell transplantationHematologic malignanciesImprove patient outcomesRNA splicing machineryImmune evasionPrognostic toolTGF-betaTherapyEffective treatmentBeyond HMAs: Novel Targets and Therapeutic Approaches
Getz T, Bewersdorf J, Kewan T, Stempel J, Bidikian A, Shallis R, Stahl M, Zeidan A. Beyond HMAs: Novel Targets and Therapeutic Approaches. Seminars In Hematology 2024, 61: 358-369. PMID: 39389839, DOI: 10.1053/j.seminhematol.2024.08.001.Peer-Reviewed Original ResearchCitationsConceptsAcute myeloid leukemiaDelays progression to acute myeloid leukemiaHeterogeneous group of clonal hematopoietic disordersGroup of clonal hematopoietic disordersMolecular International Prognostic Scoring SystemRandomized phase 3 clinical trialProgression to acute myeloid leukemiaInternational Prognostic Scoring SystemLower-risk MDS patientsRisk stratification of patientsPhase 3 clinical trialsCombination of azacitidineHypomethylating agent combinationsCurrent treatment landscapeFirst line therapyPrognostic scoring systemBiomarker-directed therapiesClonal hematopoietic disordersLack of therapeutic agentsStratification of patientsEarly phase trialsErythropoiesis stimulating agentsTreated with therapiesVariable clinical featuresStandard of care
2023
Antibody-drug conjugates for urothelial carcinoma.
Thomas J, Sun M, Getz T, Ho B, Nauseef JT, Tagawa ST. Antibody-drug conjugates for urothelial carcinoma. Urol Oncol 2023, 41: 420-428. PMID: 37419845, DOI: 10.1016/j.urolonc.2023.06.006.Peer-Reviewed Original Research
2019
Rapid-Onset Vancomycin-Induced Thrombocytopenia With Reexposure.
Getz TM, Packer CD. Rapid-Onset Vancomycin-Induced Thrombocytopenia With Reexposure. Ann Pharmacother 2019, 53: 1259-1261. PMID: 31353923, DOI: 10.1177/1060028019867433.Peer-Reviewed Case Reports and Technical NotesMicrobiomes of Inflammatory Thoracic Aortic Aneurysms Due to Giant Cell Arteritis and Clinically Isolated Aortitis Differ From Those of Non-Inflammatory Aneurysms.
Getz TM, Hoffman GS, Padmanabhan R, Villa-Forte A, Roselli EE, Blackstone E, Johnston D, Pettersson G, Soltesz E, Svensson LG, Calabrese LH, Clifford AH, Eng C. Microbiomes of Inflammatory Thoracic Aortic Aneurysms Due to Giant Cell Arteritis and Clinically Isolated Aortitis Differ From Those of Non-Inflammatory Aneurysms. Pathog Immun 2019, 4: 105-123. PMID: 30993253, DOI: 10.20411/pai.v4i1.269.Peer-Reviewed Original ResearchThe Microbiome of Temporal Arteries.
Hoffman GS, Getz TM, Padmanabhan R, Villa-Forte A, Clifford AH, Funchain P, Sankunny M, Perry JD, Blandford A, Kosmorsky G, Lystad L, Calabrese LH, Eng C. The Microbiome of Temporal Arteries. Pathog Immun 2019, 4: 21-38. PMID: 30993251, DOI: 10.20411/pai.v4i1.270.Peer-Reviewed Original Research
2018
The microbiome in PTEN hamartoma tumor syndrome.
Byrd V, Getz T, Padmanabhan R, Arora H, Eng C. The microbiome in PTEN hamartoma tumor syndrome. Endocr Relat Cancer 2018, 25: 233-243. PMID: 29233840, DOI: 10.1530/ERC-17-0442.Peer-Reviewed Original Research
2016
Quantum dot-mediated delivery of siRNA to inhibit sphingomyelinase activities in brain-derived cells.
Getz T, Qin J, Medintz IL, Delehanty JB, Susumu K, Dawson PE, Dawson G. Quantum dot-mediated delivery of siRNA to inhibit sphingomyelinase activities in brain-derived cells. J Neurochem 2016, 139: 872-885. PMID: 27622309, DOI: 10.1111/jnc.13841.Peer-Reviewed Original Research
Academic Achievements & Community Involvement
Copy Link
Activities
activity Therapeutic Advances in Hematology
02/01/2025 - PresentJournal ServiceRevieweractivity American Society of Hematology
10/01/2022 - PresentProfessional OrganizationsMemberactivity American Society of Clinical Oncology
07/01/2023 - PresentProfessional OrganizationsMemberactivity European Hematology Association
2024 - PresentProfessional OrganizationsMember
News
Copy Link
News
- December 09, 2025
Yale research advances presented at American Society of Hematology annual meeting
- December 31, 2024
Accolades, Awards & Honors
- December 18, 2024
Yale research advances presented at American Society of Hematology annual meeting
- August 16, 2023
Welcome New Postdocs, Postgrads, Fellows, Faculty & Staff! (August 2023)
Get In Touch
Copy Link
Contacts
Mailing Address
Yale Cancer Center
333 Cedar Street, PO Box 208028
New Haven, Connecticut 06520
United States